A US startup, Heliospect Genomics, is offering to screen embryos for IQ, charging up to $50,000 for 100 embryos. The company's controversial service uses genomic prediction, allowing parents to select embryos based on traits like intelligence, height, and mental health risks. While this technology is legal in the US, it raises significant ethical concerns about genetic enhancement and inequality. Critics warn it could normalize "superior" genetics, while supporters claim it could lead to healthier, smarter children. Heliospect is still in development, with plans to officially launch soon.
Download the medial app to read full posts, comements and news.